Daniel Tan Shao Weng

36PUBLICATIONS
277CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Jul 10, 2026
Rethinking Molecular Profiling Post First-Line Osimertinib.

|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

|Jun 14, 2025
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

Timothy A Yap, David S P Tan, Anastasios Stathis

|Jun 01, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.

Zofia Piotrowska, Antonio Passaro, Danny Nguyen

Pageof 6

Frequent Collaborators

7 joint publications

Anders Jacobsen Skanderup

5 joint publications

Benjamin J Solomon

5 joint publications

Aaron C Tan

4 joint publications

Vivek Subbiah